SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer
NCT07683221
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
47
Enrollment
OTHER
Sponsor class
Conditions
Pancreatic Cancer
Interventions
DRUG:
SBRT + Ipilimumab N01 + Sintilimab + AG Chemotherapy
Sponsor
Shandong Cancer Hospital and Institute